A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach

Trial Profile

A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs PF 4965842 (Primary) ; PF 4965842 (Primary)
  • Indications Atopic dermatitis
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Oct 2017 Status changed from recruiting to completed.
    • 05 Sep 2017 Planned End Date changed from 15 Sep 2017 to 1 Sep 2017.
    • 05 Sep 2017 Planned primary completion date changed from 15 Sep 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top